Trial Profile
Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkins Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Mar 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 26 Aug 2013 New trial record